Aclaris Therapeutics, Inc. – Special Call

William Roberts
Senior VP of Corporate Communications & Investor Relations

Good morning, everyone. Good to see everybody here. My name is Will Roberts. I’m the Head of Comms for Aclaris, and I’m thrilled to be the first person to welcome you to our 2025 R&D Day up here in New York. Thanks to everybody in the room. Really appreciate you showing up. It’s early. We know it. The weather is not ideal, but it’s good to see everybody here. And to the folks attending on the webcast, thank you guys as well. So the cool thing is that I get to take care of what I think is the most anticipated part of the presentation, the forward-looking statements.

So before we get going on the presentation, I want to remind everybody that today’s presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These are our judgment as of today, October 14, 2025, and may involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the content of this presentation. If you want more information on our risks and uncertainties, please refer to our filings with